C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
Go NoguchiNoboru NakaigawaSusumu UmemotoKota KobayashiYosuke ShibataSohgo TsutsumiMasato YasuiShinji OhtakeTakahisa SuzukiKimito OsakaKentaro MuraokaHisashi HasumiKeiichi KondoYuka IgarashiTetsuro SasadaTakeshi KishidaMasahiro YaoPublished in: Cancer chemotherapy and pharmacology (2020)
Our results indicated that the CRP level at 1 month after treatment with nivolumab appears to be a promising predictive biomarker for response to nivolumab treatment in patients with mRCC. It is clinically useful to be able to predict the effect within a short period. Further prospective trials are needed to prove these preliminary findings.
Keyphrases